The report provides a detailed analysis essential for establishing an Imipramine Hydrochloride production plant. It encompasses all critical aspects necessary for Imipramine Hydrochloride production, including the cost of Imipramine Hydrochloride production, Imipramine Hydrochloride plant cost, Imipramine Hydrochloride production costs, and the overall Imipramine Hydrochloride production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Imipramine Hydrochloride production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Imipramine Hydrochloride is an effective medication for the treatment of depression and anxiety. It is widely used as an immediate treatment for endogenous depression, more particularly. Moreover, it is often utilized as an antidepressant medicine to treat major depressive disorder (MDD) and bipolar depression by increasing the levels of serotonin and norepinephrine in the brain that are responsible for regulating mood. Moreover, it also finds its applications in the treatment of enuresis (bed-wetting) in children, generalized anxiety disorders, dysthymia, and panic disorder. It is also sometimes used for the treatment of attention deficit hyperactivity disorder (ADHD), which is associated with impulsivity and hyperactivity in patients.
The market for Imipramine Hydrochloride is majorly driven by its wide usage as an antidepressant for the treatment of moderate to severe depression and managing anxiety disorders, which significantly promotes its demand in the medical and health & wellness industries. Moreover, its application as a medication in the treatment of bed-wetting in children, panic disorder, agitation/hyperactivity, and other anxiety disorders further enhances its demand in the medical and pharmaceutical industries. Furthermore, several factors influence industrial Imipramine Hydrochloride procurement, such as the availability and cost of production of Imipramine Hydrochloride's raw materials (Shikimic acid), cost and pricing, compliance with medical regulations, quality standards, technological advancements, environmental considerations, sustainability practices, distribution (including trading and shipping), logistics, safety standards, etc.
Raw Material for Imipramine Hydrochloride Production
According to the Imipramine Hydrochloride production plant project report, the major raw materials for Imipramine Hydrochloride production include Iminostilbene - 3-Dimethylaminopropylchloride-Sodium Amide.
Manufacturing Process of Imipramine Hydrochloride
The extensive Imipramine Hydrochloride production cost report consists of the following industrial production process:
- Production via Alkylation: This method of production involves alkylation of 10,11-dihydro-5H-dibenz[b,f]azepine with 3-dimethylaminopropylchloride, which results in the production of 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f] azepine or Imipramine. The reaction mentioned above propagates in the presence of sodium amide as a catalyst. Further, the obtained product 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f] azepine/Imipramine is combined with hydrochloric acid to obtain Imipramine Hydrochloride as the final product.
Imipramine Hydrochloride belongs to the family of tricyclic antidepressants. The compound appears as an odorless, white to off-white crystalline powder. The compound is readily soluble in water, alcohol, and acetone but does not dissolve in ether and benzene. Moreover, its molecular formula is C19H25ClN2, and its molecular weight is 316.9 g/mol. It serves as a medication in the pharmaceutical industry for the treatment of depression. This drug is often marketed with several other names, which include Tofranil, Chimoreptin, Imizine, and Venefon, and is available in the form of oral tablets. Compared to certain other members of this treatment category, it has a less sedative impact. The IUPAC name of the compound is 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; hydrochloride.